Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Wyoming for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Wyoming only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Wyoming (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Iloabueke Chineke (NPI 1740700798)

Field	Value
Entity Type	Individual
Organization	Iloabueke Chineke
Address	6501 E 2nd St
City	Casper
State	WY
ZIP	82609
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 21, 2017

Payer Source	Total Paid
Medicare	$1.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the available data: total Medicare revenue is $1.2M while there is no Medicaid billing on file, so Medicare dominates the reported payer mix and overall revenue scale. Analysts should treat Medicare as the primary commercial signal for this NPI rather than expecting Medicaid activity.

Revenue is highly concentrated in a few high-cost drug lines: the precomputed top 3 Medicare codes account for 79.2% of this provider’s Medicare revenue, driven by J9271 ($765.6K, 64.7%), J0897 ($99.2K, 8.4%), and J1449 ($72.6K, 6.1%). This concentration indicates the business is heavily dependent on a small set of injectable oncology agents for the bulk of its Medicare receipts.

The code mix is consistent with a medical oncology infusion practice that also bills for office E/M and supportive medications: J9271 (pembrolizumab) shows 17.4K claims at $44 avg paid/claim and dominates revenue, and supportive/infectious prophylaxis and growth‑factor agents such as J0897 (5.2K claims, $19 avg paid/claim) and J1449 (2.9K claims, $25 avg) make up the next largest shares. Coupled with chemotherapy administration codes such as 96413 (257 claims, $103 avg, $26.5K) and add‑ons 96417/96415, this profile points to regular infusion throughput and on‑site drug administration.

There is a measurable but limited radiation delivery footprint on the billings: G6015 contributes $35.2K (3.0% of Medicare revenue) with a national rank of #1175 of 1429 providers (18th percentile, typical), and related RT delivery codes G6012/G6013/G6002 appear at smaller volumes. These radiation codes are present but represent a minority of revenue, suggesting radiation services are either ancillary to the oncology infusion practice or billed infrequently relative to systemic therapy.

Competitive standing is modest to mixed across top items: for the primary revenue driver J9271 the provider ranks #529 of 1841 nationally (71th percentile; typical, unremarkable volume), for J0897 the rank is #2699 of 10057 (73th percentile; typical), while J1449 ranks #112 of 161 (25th percentile; typical). Overall, the provider is not a dominant national player for these agents but participates at a typical volume for pembrolizumab and denosumab and at a lower percentile for eflapegrastim.

One notable statistical outlier in service mix is high‑level E/M: 99215 accounts for 451 claims and $63.1K (5.3% of Medicare revenue) and is flagged as an extreme outlier (rank #2473 of 145531, 98th percentile). This indicates an unusually high volume of high‑acuity established‑patient office encounters relative to national peers and may reflect complex follow‑up visits tied to oncology management.

Operational throughput is supported by frequent ancillary and diagnostic items: lab codes such as 85025 (661 claims, $8 avg, $5.3K) and 80053 (519 claims, $10 avg, $5.2K) and blood‑draw 36415 (420 claims, $8 avg, $3.4K) show routine monitoring activity consistent with ongoing systemic therapy. The presence of infusion‑timing codes (96365/96367 and add‑on hours 96415) further supports regular infusion sessions and monitoring infrastructure.

This NPI has been active for several years (NPI enumerated 2017-06-21 (~9 years ago)), so the concentrated revenue profile in expensive oncology injectables plus sustained E/M and infusion volumes likely reflects an established oncology practice rather than a new or transient billing pattern. Given the reliance on a small set of high‑cost drugs, payers and analysts should track utilization and contracting for those agents when evaluating risk and network value for this provider.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,400	$40	$765.6K
J0897	Injection, denosumab, 1 mg	5,220	$20	$99.2K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,900	$30	$72.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	450	$140	$63.1K
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	120	$290	$35.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	260	$100	$26.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	260	$100	$25.2K
J1627	Injection, granisetron, extended-release, 0.1 mg	4,200	$10	$21K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	410	$20	$9.5K
J0185	Injection, aprepitant, 1 mg	7,150	$1	$7.2K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Wyoming Distribution

Iloabueke Chineke — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Wyoming

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	12,500	$40	$528K
G6015	3	10	200	$290	$165.3K
J1449	2	10	5,740	$30	$147.8K
J0897	7	50	1,800	$20	$51.1K
77014	4	10	320	$40	$47.8K
96413	2	10	150	$100	$22.9K
G6012	2	10	120	$190	$22.4K
J1627	2	10	4,600	$1	$21.1K
G6013	3	10	40	$190	$18.7K
99214	185	780	100	$80	$14.8K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Iloabueke Chineke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nathan Steinle	CA	Retina Specialist (Ophthalmology) Physician	$9.5M	$0
Prema Abraham	SD	Retina Specialist (Ophthalmology) Physician	$7.1M	$0
Kyle Thompson	ID	Retina Specialist (Ophthalmology) Physician	$4.5M	$0
Douglas Holmes	WY	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Mitchell Goff	UT	Retina Specialist (Ophthalmology) Physician	$3.8M	$0
Richard Kinsey	TN	Anatomic Pathology & Clinical Pathology Physician	$3.3M	$147.3K
Brendan Girschek	AZ	Ophthalmology Physician	$3.2M	$0
John Purviance	WY	Radiation Oncology Physician	$2.5M	$0
Cary Chisholm	TX	Anatomic Pathology & Clinical Pathology Physician	$2.5M	$24.7K
Stacey Wells	AK	Radiation Oncology Physician	$2M	$0

Nearby Providers

Other providers in the same ZIP code as Iloabueke Chineke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Northwest Community Action Programs Of Wyoming, Inc.	WY	Developmentally Disabled Services Day Training Agency	$0	$25.8M
Community Health Center Of Central Wyoming, Inc.	WY	Federally Qualified Health Center (FQHC)	$0	$15.3M
Emg Casper Mw LLC	WY	Assisted Living Facility	$0	$5.9M
Casper Children's Center, LLC	WY	Pediatrics Physician	$0	$4M
Wyoming Behavioral Institute	WY	Psychiatric Hospital	$0	$2.7M
Stephen Brown	WY	Child & Adolescent Psychiatry Physician	$0	$2.4M
2nd Street Dental, LLC	WY	Dental Clinic/Center	$0	$2.4M
Solutions Counseling Services LLC	WY	Community/Behavioral Health Agency	$0	$2.1M
Surfin Smiles LLC	WY	Pediatric Dentistry	$0	$2M
Elie Fahed	WY	Medical Oncology Physician	$1.9M	$0

Iloabueke Chineke — Billing Profile & Reimbursement Data

Sign up for Iloabueke Chineke — Billing Profile & Reimbursement Data policy alerts

Iloabueke Chineke — Billing Profile & Reimbursement Data

Sign up for Iloabueke Chineke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References